Financial Statements and Highlights | Takeda Investor Relations

glasses laying on a book with stock options

Financial Highlights

Loading feed metadata...

Sign up for our investors newsletter

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Recent News

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

February 24, 2025

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

January 30, 2025

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

January 30, 2025

Explore

Investor Events

Access our IR events calendar and recaps of past events

Our Pipeline

Learn more about our dynamic and diverse pipeline